Related references
Note: Only part of the references are listed.DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma
Priya Choudhry et al.
LEUKEMIA (2020)
A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma
Joseph Mikhael et al.
BLOOD (2019)
The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma
Laura Moreno et al.
CLINICAL CANCER RESEARCH (2019)
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
T. Facon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Class 1 HDAC and HDAC6 inhibition inversely regulates CD38 induction in myeloma cells via interferon-α and ATRA
Ariunzaya Bat-Erdene et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience
Kristine A. Frerichs et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2018)
Immunomodulatory effects of CD38-targeting antibodies
Niels W. C. J. van de Donk
IMMUNOLOGY LETTERS (2018)
Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD+
F. Morandi et al.
ONCOIMMUNOLOGY (2018)
IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos
Pasquale L. Fedele et al.
BLOOD (2018)
Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients
Rimke Oostvogels et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation
Federica Costa et al.
ONCOTARGET (2017)
Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab
Jakub Krejcik et al.
CLINICAL CANCER RESEARCH (2017)
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
Ajai Chari et al.
BLOOD (2017)
Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma
Xiaoyan Feng et al.
CLINICAL CANCER RESEARCH (2017)
A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma
Thomas Martin et al.
BLOOD (2017)
Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab
Estefania Garcia-Guerrero et al.
BLOOD (2017)
Re-challenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach
Evren Alici et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide
H. Jiang et al.
LEUKEMIA (2016)
Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication
Gang An et al.
BLOOD (2016)
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
Saad Z. Usmani et al.
BLOOD (2016)
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
Inger S. Nijhof et al.
BLOOD (2016)
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
Jakub Krejcik et al.
BLOOD (2016)
Monoclonal antibodies targeting CD38 in hematological malignancies and beyond
Niels W. C. J. van de Donk et al.
IMMUNOLOGICAL REVIEWS (2016)
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
Sagar Lonial et al.
LANCET (2016)
Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates With Progression of Human Myeloma
Alberto L. Horenstein et al.
MOLECULAR MEDICINE (2016)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Panobinostat plus bortezomib and dexamethasone for relapsed myeloma
Guy Pratt
Lancet Haematology (2016)
Immunotherapies targeting CD38 in Multiple Myeloma
Djordje Atanackovic et al.
ONCOIMMUNOLOGY (2016)
Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab
I. S. Nijhof et al.
LEUKEMIA (2015)
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
H. M. Lokhorst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
NAD+-Metabolizing Ectoenzymes in Remodeling Tumor-Host Interactions: The Human Myeloma Model
Alberto L. Horenstein et al.
CELLS (2015)
Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche
Valeria Quarona et al.
MARROW (2015)
Multiple Myeloma Preface
Kenneth C. Anderson
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2014)
Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules
Marina Bolzoni et al.
EXPERIMENTAL HEMATOLOGY (2013)
Anti-CD38 Antibody Therapy: Windows of Opportunity Yielded by the Functional Characteristics of the Target Molecule
Antonella Chillemi et al.
MOLECULAR MEDICINE (2013)
A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes
Alberto L. Horenstein et al.
ONCOIMMUNOLOGY (2013)
T Cell Suppression by Osteoclasts In Vitro
Francesco Grassi et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2011)
All-trans retinoic acid and a novel synthetic retinoid tamibarotene (Am80) differentially regulate CD38 expression in human leukemia HL-60 cells: possible involvement of protein kinase C-δ
Akira Uruno et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2011)
MEDICAL PROGRESS Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Cancer biology and NuRD: a multifaceted chromatin remodelling complex
Anne Y. Lai et al.
NATURE REVIEWS CANCER (2011)
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
H. Quach et al.
LEUKEMIA (2010)
Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology
Fabio Malavasi et al.
PHYSIOLOGICAL REVIEWS (2008)
CD38 at the junction between prognostic marker and therapeutic target
Silvia Deaglio et al.
TRENDS IN MOLECULAR MEDICINE (2008)
Drug therapy: Multiple myeloma
RA Kyle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion
M Abe et al.
BLOOD (2004)
Flow cytometric detection of aneuploid CD38++ plasmacells and CD19+ B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients
AM Santonocito et al.
LEUKEMIA RESEARCH (2004)
Disordered osteoclast formation and function in a CD38 (ADP-ribosyl cyclase)-deficient mouse establishes an essential role for CD38 in bone resorption
L Sun et al.
FASEB JOURNAL (2003)
Phosphatidylinositol 3-kinases are involved in the all-trans retinoic acid-induced upregulation of CD38 antigen on human haematopoietic cells
D Lewandowski et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
A novel mechanism for coupling cellular intermediary metabolism to cytosolic Ca2+ signaling via CD38/ADP-ribosyl cyclase, a putative intracellular NAD(+) sensor
L Sun et al.
FASEB JOURNAL (2002)
T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ
H Takayanagi et al.
NATURE (2000)
Share Paper
